ストックスクリーナーアプリを入手
0.7556
3.00%
0.022
アフターアワーズ：
.68
-0.0756
-10.01%
前日終値:
$0.7336
開ける：
$0.75
24時間の取引高:
526.33K
Relative Volume:
0.96
時価総額：
$20.74M
収益：
$5.61M
当期純損益:
$-55.45M
株価収益率:
-0.294
EPS:
-2.5703
ネットキャッシュフロー:
$-42.35M
1週間 パフォーマンス:
+10.74%
1か月 パフォーマンス:
+42.03%
6か月 パフォーマンス:
-1.25%
1年 パフォーマンス:
-42.32%
1日の値動き範囲:
$0.7276
$0.79
1週間の範囲:
$0.6691
$0.79
52週間の値動き範囲:
$0.4687
$2.19
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.7556 | 21.00M | 5.61M | -55.45M | -42.35M | -2.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media
Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - mshale.com
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Morningstar
Citius Oncology's LYMPHIR is in 42 institutions with near-universal coverage - Stock Titan
Citius Pharmaceuticals (CTXR) Advances 5.7% to $0.63; Key Resistance at $0.66 in FocusVolatility Surface - dars.gov.et
Citius Pharmaceuticals (CTXR) Tumbles 9.81% to $0.57 as Biotech Stock Approaches Critical SupportValue Stock Ideas - dars.gov.et
Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.490|Chg%:-0.027 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.682|Chg%:+0.040 - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals (CTXR) Slips 2%, Hovers Above Key Support at $0.49Put Flow Alert - dars.gov.et
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Nigeria
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar
Citius Oncology expands LYMPHIR launch team nationwide - scanx.trade
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals (CTXR) Edges Lower, Testing Key Support at $0.51Long Short Pair - dars.gov.et
Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0 - TradingView
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals updates pipeline as investors track CTXR stock - Ad-hoc-news.de
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why - Insider Financial
Citius Pharmaceuticals Q4 2025 Earnings: EPS Miss Exceeds 45% as Pre-Revenue Biotech Navigates Clinical MilestonesAdjusted Earnings Analysis - DonanımHaber
A40MD0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):